Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia
Bulletin of Reproductive Health · 2024
DOI: 10.14341/brh12709 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin of Reproductive Health, 2024. Verfasst von E. V. Shlyakhto und 18 weiteren Autor:innen. Die Arbeit nennt 128 Literaturangaben.
Abstract (Originalsprache)
Menopausal symptoms can disrupt the life course of women at the peak of their career and family life. Currently, the most effective treatment for these manifestations is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases in itself does not exclude the possibility of prescribing MHT to relieve menopausal symptoms and improve quality of life. However, often an obstacle to the use of this type of hormonal therapy is the fear of doctors who are afraid of doing more harm to patients than good. Caution is especially important when it comes to women with underlying health conditions. Moreover, it should be recognized that there is a lack of high-quality research regarding the safety of MHT for major chronic non-infectious diseases and common comorbid conditions. The presented consensus document analyzed all currently available data obtained from clinical trials of various designs and created a set of criteria for the acceptability of prescribing MHT to women with concomitant cardiovascular and metabolic diseases. Based on the presented document, doctors of various specialties who advise women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and reasonably prescribe MHT in real practice.
Zitieren
APA
Shlyakhto, E. V., Sukhikh, G. T., Serov, V. N., Dedov, I. I., Arutyunov, G. P., Suchkov, I. A., Orlova, Y. A., Andreeva, E. N., Yureneva, S. V., Yavelov, I. S., Yarmolinskaya, M. I., Villevalde, S. V., Grigoryan, O. R., Dudinskaya, E. N., Ilyukhin, E. A., Koziolova, N. A., Sergienko, I. V., Smetnik, A. A., & Tapilskaya, N. I. (2024). Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia. Bulletin of Reproductive Health. https://doi.org/10.14341/brh12709
Vancouver
Shlyakhto EV, Sukhikh GT, Serov VN, Dedov II, Arutyunov GP, Suchkov IA, et al. Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia. Bulletin of Reproductive Health. 2024. doi:10.14341/brh12709
BibTeX
@article{Shlyakhto2024,
author = {Shlyakhto, E. V. and Sukhikh, G. T. and Serov, V. N. and Dedov, I. I. and Arutyunov, G. P. and Suchkov, I. A. and Orlova, Y. A. and Andreeva, E. N. and Yureneva, S. V. and Yavelov, I. S. and Yarmolinskaya, M. I. and Villevalde, S. V. and Grigoryan, O. R. and Dudinskaya, E. N. and Ilyukhin, E. A. and Koziolova, N. A. and Sergienko, I. V. and Smetnik, A. A. and Tapilskaya, N. I.},
title = {Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia},
journal = {Bulletin of Reproductive Health},
year = {2024},
doi = {10.14341/brh12709}
}
EUVIMED